98 related articles for article (PubMed ID: 16445667)
1. Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer.
Kanasugi M; Aoki D; Suzuki N; Susumu N; Nakata S; Horiuchi M; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2006; 16(1):409-15. PubMed ID: 16445667
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
5. Clinical Correlation of the Histoculture Drug Response Assay for Head and Neck Cancer.
Hoffman RM
Methods Mol Biol; 2018; 1760():83-92. PubMed ID: 29572796
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
7. Clinical Correlation of the Histoculture Drug Response Assay in Gastrointestinal Cancer.
Hoffman RM
Methods Mol Biol; 2018; 1760():61-72. PubMed ID: 29572794
[TBL] [Abstract][Full Text] [Related]
8. Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer.
Hoffman RM; Jung PS; Kim MB; Nam JH
Methods Mol Biol; 2018; 1760():73-81. PubMed ID: 29572795
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
10. [High clinical predictability of histoculture drug response assay (HDRA) for drug-sensitivity of cancer of the digestive organs].
Kubota T; Furukawa T; Kitajima M
Gan To Kagaku Ryoho; 1993 Mar; 20(4):461-6. PubMed ID: 8452384
[TBL] [Abstract][Full Text] [Related]
11. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer.
Fujita Y; Hiramatsu M; Kawai M; Nishimura H; Miyamoto A; Tanigawa N
Oncol Rep; 2009 Feb; 21(2):499-505. PubMed ID: 19148528
[TBL] [Abstract][Full Text] [Related]
12. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
13. Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer.
Hoffman RM; Tanino H
Methods Mol Biol; 2018; 1760():93-100. PubMed ID: 29572797
[TBL] [Abstract][Full Text] [Related]
14. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
15. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
16. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
17. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
18. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
19. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
20. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
Gallion H; Christopherson WA; Coleman RL; DeMars L; Herzog T; Hosford S; Schellhas H; Wells A; Sevin BU
Int J Gynecol Cancer; 2006; 16(1):194-201. PubMed ID: 16445633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
